Cancer-screen blood test wins tepid support from US drug advisory panel
FDA committee expressed concerns about effectiveness and overall benefits for a product that failed a UK study earlier this year
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
9 publishers have covered this in 12 articles since 21 Sept 2026. STAT published first, on 21 September at 17:58 UTC; NPR Health followed 40h 01m later. The most recent article, from MedPageToday.com - medical news for physicians, appeared on 25 September at 20:04 UTC.
Outlets reporting it: NPR Health (major outlet), News Feed (major outlet), STAT, MarketWatch, Quartz, Scientific American, South China Morning Post, MedPageToday.com - medical news for physicians, Inc..
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- STATSTAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
- NPR HealthWill FDA advisers recommend a multi-cancer blood test for approval? They'll vote
- MarketWatchFDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.
- QuartzFDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance
- STATSTAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
- Scientific AmericanBlood test for multiple cancers clears crucial hurdle on track to FDA approval
- News FeedCancer-screen blood test wins tepid support from US drug advisory panel
- South China Morning PostUS regulators back multi-cancer blood test – but Hong Kong doctors remain cautious
- MedPageToday.com - medical news for physiciansFDA Advisors Recommend Galleri Multicancer Blood Test
- Inc.This Controversial Cancer Test Just Passed a Key FDA Vote. Here’s Why It’s Dividing Experts
- QuartzFDA advisory panel endorsed Grail's multi-cancer blood test in a split vote
- MedPageToday.com - medical news for physiciansDid FDA Advisors Support a Cancer Early-Detection Blood Test?
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Cancer-screen blood test wins tepid support from US drug advisory panel News Feed ·
- Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote NPR Health ·
- Did FDA Advisors Support a Cancer Early-Detection Blood Test? MedPageToday.com - medical news for physicians
- FDA advisory panel endorsed Grail's multi-cancer blood test in a split vote Quartz
- This Controversial Cancer Test Just Passed a Key FDA Vote. Here’s Why It’s Dividing Experts Inc.
- FDA Advisors Recommend Galleri Multicancer Blood Test MedPageToday.com - medical news for physicians
Show 6 more sources
- US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious South China Morning Post
- Blood test for multiple cancers clears crucial hurdle on track to FDA approval Scientific American
- STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks STAT
- FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance Quartz
- FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow. MarketWatch
- STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators STAT